Association of dopamine, serotonin, and nicotinic gene polymorphisms with methylphenidate response in ADHD

Hema Tharoor, Elizabeth A. Lobos, Richard D. Todd, Angela M. Reiersen

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Gene polymorphisms of the 3′ untranslated region (3′-UTR) of the dopamine transporter (DAT1), Dopamine receptor exon 3 D4 variable number tandem repeat (DRD4VNTR), nicotinic acetylcholine receptor alpha 4 subunit (CHRNA4) and serotonin transporter promoter (SLC6A4-5HTTLPR) are under consideration as potential risk factors for attention-deficit/hyperactivity disorder (ADHD). A post-hoc attempt was made to investigate the association between the allelic variations of these candidate genes and retrospective parental report of response to methylphenidate in an ADHD-enriched, population-based twin sample. Subjects (N = 243) were selected from the twin sample based on parent report that the child had been treated with methylphenidate for ADHD symptoms. The functional polymorphisms screened were the VNTR located in the 3′-UTR of the dopamine transporter, DRD4 VNTR, CHRNA4 (rs1044396 and rs6090384) and the long (LA and LG) and short (S) forms of the serotonin transporter promoter region. Logistic regression did not demonstrate a significant association between methylphenidate treatment response and the relevant polymorphisms. The sample size had high power to detect effect sizes similar to those reported in some prior methylphenidate pharmacogenetic studies; however, the categorical (yes/no) measure of parent-reported treatment response may not have been sensitive enough to pick up statistically significant differences in treatment response based on genotype. Further studies including quantitative measures of treatment response are warranted.

Original languageEnglish
Pages (from-to)527-530
Number of pages4
JournalAmerican Journal of Medical Genetics, Part B: Neuropsychiatric Genetics
Volume147
Issue number4
DOIs
Publication statusPublished - 05-06-2008
Externally publishedYes

Fingerprint

Methylphenidate
Attention Deficit Disorder with Hyperactivity
Dopamine
Serotonin
Serotonin Plasma Membrane Transport Proteins
Dopamine Plasma Membrane Transport Proteins
3' Untranslated Regions
Genes
Minisatellite Repeats
Dopamine Receptors
Nicotinic Receptors
Therapeutics
Genetic Promoter Regions
Sample Size
Exons
Logistic Models
Genotype
Population

All Science Journal Classification (ASJC) codes

  • Genetics(clinical)
  • Neuropsychology and Physiological Psychology
  • Neuroscience(all)

Cite this

Tharoor, Hema ; Lobos, Elizabeth A. ; Todd, Richard D. ; Reiersen, Angela M. / Association of dopamine, serotonin, and nicotinic gene polymorphisms with methylphenidate response in ADHD. In: American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics. 2008 ; Vol. 147, No. 4. pp. 527-530.
@article{0e19e2c19ef64848931c2a9a809d4587,
title = "Association of dopamine, serotonin, and nicotinic gene polymorphisms with methylphenidate response in ADHD",
abstract = "Gene polymorphisms of the 3′ untranslated region (3′-UTR) of the dopamine transporter (DAT1), Dopamine receptor exon 3 D4 variable number tandem repeat (DRD4VNTR), nicotinic acetylcholine receptor alpha 4 subunit (CHRNA4) and serotonin transporter promoter (SLC6A4-5HTTLPR) are under consideration as potential risk factors for attention-deficit/hyperactivity disorder (ADHD). A post-hoc attempt was made to investigate the association between the allelic variations of these candidate genes and retrospective parental report of response to methylphenidate in an ADHD-enriched, population-based twin sample. Subjects (N = 243) were selected from the twin sample based on parent report that the child had been treated with methylphenidate for ADHD symptoms. The functional polymorphisms screened were the VNTR located in the 3′-UTR of the dopamine transporter, DRD4 VNTR, CHRNA4 (rs1044396 and rs6090384) and the long (LA and LG) and short (S) forms of the serotonin transporter promoter region. Logistic regression did not demonstrate a significant association between methylphenidate treatment response and the relevant polymorphisms. The sample size had high power to detect effect sizes similar to those reported in some prior methylphenidate pharmacogenetic studies; however, the categorical (yes/no) measure of parent-reported treatment response may not have been sensitive enough to pick up statistically significant differences in treatment response based on genotype. Further studies including quantitative measures of treatment response are warranted.",
author = "Hema Tharoor and Lobos, {Elizabeth A.} and Todd, {Richard D.} and Reiersen, {Angela M.}",
year = "2008",
month = "6",
day = "5",
doi = "10.1002/ajmg.b.30637",
language = "English",
volume = "147",
pages = "527--530",
journal = "American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics",
issn = "1552-4841",
publisher = "Wiley-Liss Inc.",
number = "4",

}

Association of dopamine, serotonin, and nicotinic gene polymorphisms with methylphenidate response in ADHD. / Tharoor, Hema; Lobos, Elizabeth A.; Todd, Richard D.; Reiersen, Angela M.

In: American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics, Vol. 147, No. 4, 05.06.2008, p. 527-530.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Association of dopamine, serotonin, and nicotinic gene polymorphisms with methylphenidate response in ADHD

AU - Tharoor, Hema

AU - Lobos, Elizabeth A.

AU - Todd, Richard D.

AU - Reiersen, Angela M.

PY - 2008/6/5

Y1 - 2008/6/5

N2 - Gene polymorphisms of the 3′ untranslated region (3′-UTR) of the dopamine transporter (DAT1), Dopamine receptor exon 3 D4 variable number tandem repeat (DRD4VNTR), nicotinic acetylcholine receptor alpha 4 subunit (CHRNA4) and serotonin transporter promoter (SLC6A4-5HTTLPR) are under consideration as potential risk factors for attention-deficit/hyperactivity disorder (ADHD). A post-hoc attempt was made to investigate the association between the allelic variations of these candidate genes and retrospective parental report of response to methylphenidate in an ADHD-enriched, population-based twin sample. Subjects (N = 243) were selected from the twin sample based on parent report that the child had been treated with methylphenidate for ADHD symptoms. The functional polymorphisms screened were the VNTR located in the 3′-UTR of the dopamine transporter, DRD4 VNTR, CHRNA4 (rs1044396 and rs6090384) and the long (LA and LG) and short (S) forms of the serotonin transporter promoter region. Logistic regression did not demonstrate a significant association between methylphenidate treatment response and the relevant polymorphisms. The sample size had high power to detect effect sizes similar to those reported in some prior methylphenidate pharmacogenetic studies; however, the categorical (yes/no) measure of parent-reported treatment response may not have been sensitive enough to pick up statistically significant differences in treatment response based on genotype. Further studies including quantitative measures of treatment response are warranted.

AB - Gene polymorphisms of the 3′ untranslated region (3′-UTR) of the dopamine transporter (DAT1), Dopamine receptor exon 3 D4 variable number tandem repeat (DRD4VNTR), nicotinic acetylcholine receptor alpha 4 subunit (CHRNA4) and serotonin transporter promoter (SLC6A4-5HTTLPR) are under consideration as potential risk factors for attention-deficit/hyperactivity disorder (ADHD). A post-hoc attempt was made to investigate the association between the allelic variations of these candidate genes and retrospective parental report of response to methylphenidate in an ADHD-enriched, population-based twin sample. Subjects (N = 243) were selected from the twin sample based on parent report that the child had been treated with methylphenidate for ADHD symptoms. The functional polymorphisms screened were the VNTR located in the 3′-UTR of the dopamine transporter, DRD4 VNTR, CHRNA4 (rs1044396 and rs6090384) and the long (LA and LG) and short (S) forms of the serotonin transporter promoter region. Logistic regression did not demonstrate a significant association between methylphenidate treatment response and the relevant polymorphisms. The sample size had high power to detect effect sizes similar to those reported in some prior methylphenidate pharmacogenetic studies; however, the categorical (yes/no) measure of parent-reported treatment response may not have been sensitive enough to pick up statistically significant differences in treatment response based on genotype. Further studies including quantitative measures of treatment response are warranted.

UR - http://www.scopus.com/inward/record.url?scp=45149090868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45149090868&partnerID=8YFLogxK

U2 - 10.1002/ajmg.b.30637

DO - 10.1002/ajmg.b.30637

M3 - Article

VL - 147

SP - 527

EP - 530

JO - American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

JF - American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

SN - 1552-4841

IS - 4

ER -